BioTime, Hospira amend Hextend licensing pact

By Ted A. Knutson

Washington, Jan. 13 - BioTime Inc. said it and Hospira Inc. entered into an amendment Jan. 9 to their exclusive license agreement for BioTime's Hextend, adding Australia, Mexico and the countries of Central America and South America to Hospira's marketing territory.

Hospira will be responsible for obtaining all government regulatory approvals required for the sale and use of Hextend in those countries.

All sales in the new territory will be added to U.S. and Canadian sales for the purpose of determining the royalties payable to BioTime.

Hextend is BioTime's proprietary physiologically balanced blood plasma volume expander and is presently distributed by Hospira in the United States and Canada.

BioTime is an Emeryville, Calif.-based biotechnology company.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.